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DEFINED PATIENT POPULATIONS
Despite enormous progress in the basic sciences and substantial
progress in identifying biochemical and genetic mechanisms of
many skin diseases, it is the clinical scientist who now holds the
key to unraveling most of skin’s mysteries. Knowledge about the
genetic code and sequencing the human genome have not
replaced the physicians who take care of patients. Until now,
and for patients with single gene defects, biologic samples from
a limited number of patients have allowed laboratory scientists
to identify those diseases that are caused by defects in single
genes. As examples, sex-linked ichthyosis (OMIM #308100
ICHTHYOSIS, X-LINKED) and keratosis follicularis (OMIM
#124200 DARIER-WHITE DISEASE) come to mind. On the
other hand, for genetically complex diseases, which a¡ect the
majority of patients who seek care from physicians who know
about skin, the issues are much more di⁄cult. In this issue, the
paper byAlamartine and colleagues from the Renal Transplanta-
tion and Dermatology Services in Saint Etienne, France illus-
trates this issue well (page 99). These investigators sought to
identify genetic factors that might contribute to the high fre-
quency of skin cancer that follows immunosuppression, as is
required to protect allograft kidneys after transplantation. Their
search began with knowledge that the cytokine Interleukin-10
(IL-10) plays roles in ultraviolet radiation-mediated immunosup-
pression, and it was complemented by an older, established litera-
ture about the critical role of immunosuppression in cutaneous
carcinogenesis. Their aim was to search for IL-10 gene promoter
polymorphisms in the patients who had developed skin cancer.
Key to the experimental work were 70 kidney transplant recipi-
ents who developed squamous cell or basal cell carcinomas,
matched with 70 healthy control subjects and with 70 transplant
patients who had not developed cancer.The idea of a polymorph-
ism is that patients with cancer might be more likely to have a
‘minor’ di¡erence in the genetic sequence that regulates the
expression of the gene and consequently the expression of
the IL-10 protein. After the genetic studies were performed, the
investigators then examined IL-10 secretion capability in a sub-
group of 40 patients by in vitro stimulation of peripheral blood
mononuclear cells. It is the nature of scienti¢c reporting that we
would not be discussing this article if the answer had not been
informative. In fact, IL-10 genotypes were di¡erently distributed
in the kidney transplant recipients who developed a skin carcino-
ma, but especially in those who developed squamous cell carci-
nomas. Moreover, secretion of IL-10 was strongly correlated
with the predicted phenotype, and tended to be higher in pa-
tients who had developed squamous cell carcinomas. And what
this means is that a genetic factor beyond that of pigmentation
in transplant recipients plays a major, and perhaps even a domi-
nant, role in conferring susceptibility for skin cancer. Obviously,
the expression of IL-10 may not be the only factor that controls
this susceptibility. Perhaps we are closer to being able to identify
those patients who are most at risk for this preventable complica-
tion of immunosuppression. But it was the availability of a rela-
tively homogeneous population of patients with skin cancer that
made this study possible.
THERE ARE ANTIBODIES AND THEN THERE
ARE ANTIBODIES
It is possible to de¢ne scienti¢c progress as the process by which
an individual (the scientist) determines how to make ¢ner and
¢ner discriminations among observations. For example, in the
physical world, at ¢rst there was matter (such as water, identi¢ed
through direct observation), and then molecules (H2O, identi¢ed
through chemistry) and eventually particles (neutrons, protons,
and electrons, identi¢ed through physics). This process of making
¢ner and ¢ner distinctions has typi¢ed 19th, 20th, and now even
21st Century science, and it has obviously occured in medical
science, as well. In this issue Luis Diaz and his several colleagues
from all over the Western Hemisphere have added one more
important step in our understanding of pemphigus by using an
important distinction in the discipline of cutaneous immunology
(page 104). They have worked with a special cohort of patients in
a focus of endemic pemphigus in LimaoVerde, Brazil, where dis-
ease prevalence is 3.4%. (See comments above about the impor-
tance of physicians who care for patients, and the role of these
physicians in assembling well-characterized population of pa-
tients.) Endemic pemphigus foliaceus, like the sporadic form seen
in the developed world, is mediated, at least in part, by IgG anti-
bodies to desmoglein-1.The investigators had previously detected
IgG antibodies to desmoglein-1 in 97% of their patients, but IgG
antibodies were also present in 55% of normal subjects who lived
within the endemic focus. Moreover, there were progressively
lower levels of such antibodies in normal subjects in the sur-
rounding areas.Thus, there was uncertainty about the role of such
antibodies in the patients with the disease, when compared with
the subjects without the disease. The key to the study was knowl-
edge that IgG antibodies do not constitute a single population,
but, rather there are important subtypes (IgG1 through IgG4),
each with di¡ering capabilities. The investigators went ahead
and developed a highly selective assay to quantitate the subclasses
of IgG antibodies. They now report that the normal subjects did
have both IgG1 and IgG4 responses, and that the patients had
similar levels of IgG1, but much higher (19.3-fold higher) IgG4
responses. Patients in remission had weak IgG4 responses, but
74.3-fold higher IgG4 responses were associated with active dis-
ease. Finally, in 5 patients in whom they had taken blood samples
before and after the onset of clinical disease, a mean 103.1-fold rise
in IgG4 was associated with its onset. The conclusion is clear: it is
not the IgG response against desmoglien-1 that is important, but
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the IgG4 response. Not only dowe need well-de¢ned populations
of patients to make such distinctions, we still need basic scienti¢c
information to tell us how to look.
SHEDDING LIGHT ON LASER LIGHT
A growing literature documents the concept that exposure of
skin and the cells within skin to laser light at £uences below that
which produce destructive thermal e¡ects may have relatively
speci¢c e¡ects on cellular function. This fact is now making the
transition from a largely unanticipated observation to laboratory
and clinical usefulness. And it is through knowledge of mechan-
isms of action for these e¡ects that one may make re¢nements
that lead to even greater speci¢city. Progress is reported in this
issue byYu, Hsin-Su and colleagues from the Kaohsiung Medical
University in Taiwan (page 56). As noted above, it had been
known that low-energy lasers are capable of producing
energy densities so low that biologic alterations are the result
of a direct irradiation e¡ect, not thermal events, with temperature
elevations in irradiated tissues limited to less than 0.1^0.5 C.
Recently, in vitro studies had shown that low-energy lasers induce
biostimulatory e¡ects on cultured cells, inducing macrophages to
release factors that stimulate ¢broblast proliferation and ¢bro-
blasts to increase the production of pro-collagen, collagen, basic
¢broblast growth factors and rates of proliferation. He^Ne laser
treatment had been reported to stimulate IL-8 and IL-1 release
from cultured keratinocytes and to induce an increase in the rate
of keratinocyte migration and proliferation. Importantly for the
study that follows, earlier reports had indicated that low-energy
laser treatment might induce repigmentation in patients with vi-
tiligo. Three important observations are reported in the article
that follows: (1) The He^Ne laser induced a signi¢cant increase
in basic ¢broblast growth factor release from both keratinocytes
and ¢broblasts and a signi¢cant increase in nerve growth factor
release from keratinocytes. (2) Media from He^Ne laser irradiated
keratinocytes stimulated thymidine uptake, proliferation, and mi-
gration by cultured melanocytes. (3) More than half of the 30
patients with segmental-type vitiligo treated once or twice
weekly experienced signi¢cant repigmentation. We agree with
the investigators that it is reasonable to propose that He^Ne laser
irradiation does stimulate melanocyte migration and proliferation
through the relatively speci¢c release of melanocyte growth
factors and chemotactic agents, thereby providing a microenvir-
onment suitable for repigmentation.
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